Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant.
about
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownNovel vaccine development strategies for inducing mucosal immunityAsymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein BLinear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunityAdvances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsNasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization.Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection.Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria modelA modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgeniPhenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpesImmunization of mice with Lactobacillus casei expressing a beta-intimin fragment reduces intestinal colonization by Citrobacter rodentiumTherapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of lIdentification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challengeDeveloping an asymptomatic mucosal herpes vaccine: the present and the future.Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.Functional Foxp3+ CD4+ CD25(Bright+) "natural" regulatory T cells are abundant in rabbit conjunctiva and suppress virus-specific CD4+ and CD8+ effector T cells during ocular herpes infection.The herpes simplex virus type 1 latency-associated transcript inhibits phenotypic and functional maturation of dendritic cells.Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex VaccineTargeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens.Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections.Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2.Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.Needle-free vaccine delivery.A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.New concepts in herpes simplex virus vaccine development: notes from the battlefield.Bioadhesive delivery systems for mucosal vaccine delivery.The mucosal vaccine quandary: intranasal vs. sublingual immunization against influenza.Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.Sublingual therapeutic immunization with a polyvalent bacterial preparation in patients with recurrent respiratory infections: immunomodulatory effect on antigen-specific memory CD4+ T cells and impact on clinical outcome.Immunization without needles.Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses Against Herpes Infection and Disease‡.
P2860
Q21296712-F376527C-1E5D-4FB7-B9D9-CC0F59AC500FQ24607533-97B708EA-1CC7-47D5-BA5D-4F37FE5BFDB4Q30847945-73482DC3-947D-41E3-BA76-334D810F5B99Q33614657-536B6E5C-09BF-495D-B17A-9F135D95EED1Q33721641-D75F149A-2D1E-4B0E-ADFF-BE62AD54FBE0Q33725145-111D7B32-48ED-41C4-9527-3E239D5E128FQ33887085-78733C9D-63FE-4A0A-9472-D733D492C79BQ33993731-9003292C-460E-4219-BC8D-CA5BD40A683BQ34228659-03CBE306-8FD9-4268-9526-4CF3EDF3E3F8Q34398787-C52A1F39-CA14-4334-AAE2-33E47803E758Q34787042-D40D7769-C2D7-4F10-BD29-97476DBE4E29Q35113308-44EA18E4-39DE-482A-9358-E3B2595BB974Q35122383-5C14FF0D-1C4E-4A2C-B944-795B9B2FD6F6Q35487893-34DA1535-FBBF-4A69-BD64-C007C216129BQ35530236-6D887FEB-94BD-4037-BAA0-AE313C2A8430Q35745358-F7842DA1-BBC6-429E-85C7-24F835773119Q35802953-D52B9BAD-76BB-4E92-9154-901A99FCF887Q35871689-BCCE22DB-FAC3-44B3-9788-C9A48500FDD3Q35881975-8DE035CC-42BB-4443-8CBB-62FCB2E2819DQ35886523-1ECC32BB-98A3-478A-81E4-19CEBA3BD27BQ35914558-0B63AA4F-96DA-407C-B890-CCDDB252EE81Q36005107-6F06A73C-FE0A-4821-A5E4-4691CD5560F6Q36025675-1E5FA0C6-00F0-45BD-A25A-5A11F2E48767Q36339059-F9B9C178-815A-4794-884F-105D75A4A454Q36391905-EB4CAA77-515A-4B02-B45C-2EFBD9D2EFEEQ36520832-52318DF3-AB45-49B1-B0BA-E020DA907071Q36555158-61D4BC8D-BF2A-4360-8F7D-D9E7170AD163Q36898071-508DE039-9695-4229-87CD-3169F69EC6DAQ36945838-E7CF374B-271F-42A0-9645-4E46F782934EQ37118262-23DE58FE-ADCA-47CB-91ED-8A43D473C3C6Q37384857-A94CE157-AA78-4BC8-BA33-CB80835C4AFEQ37805519-4A9F24DC-728E-4FC4-A89D-4019688A4B4CQ38001862-3E276EB0-82CF-4B7F-A80B-6BE0892A177DQ41195668-C8A09411-9138-4CD4-A1BB-2CE9BE54C667Q44925699-CCEEC60E-D0B7-496D-BF51-6D0E4E045E8BQ46308392-0C029F44-B564-47BC-96E4-63497D347B1CQ50043299-FCE9C96A-9050-4E24-BA0D-4F183C57EA3E
P2860
Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Systemic immune responses indu ...... lipopeptides without adjuvant.
@en
Systemic immune responses indu ...... lipopeptides without adjuvant.
@nl
type
label
Systemic immune responses indu ...... lipopeptides without adjuvant.
@en
Systemic immune responses indu ...... lipopeptides without adjuvant.
@nl
prefLabel
Systemic immune responses indu ...... lipopeptides without adjuvant.
@en
Systemic immune responses indu ...... lipopeptides without adjuvant.
@nl
P2093
P1476
Systemic immune responses indu ...... lipopeptides without adjuvant.
@en
P2093
Estelle Loing
Helene Gras-Masse
Karima Brahimi
Lbachir BenMohamed
Yasmine Belkaid
P304
P356
10.1002/1521-4141(200208)32:8<2274::AID-IMMU2274>3.0.CO;2-C
P407
P577
2002-08-01T00:00:00Z